Peptides, particularly thymic peptides such as thymosin alpha-1, have been studied for their potential to support the thymus and the broader immune system. The thymus is a primary lymphoid organ critical for T-cell development and immune function. Research has shown that certain peptides derived from the thymus can modulate immune responses, enhance T-cell maturation, and potentially restore immune competence, especially in immunocompromised individuals or those experiencing age-related thymic involution. Clinical trials and experimental studies have explored the administration of synthetic or purified thymic peptides. Thymosin alpha-1, for example, has been used as an immunomodulatory agent in the treatment of viral infections, some cancers, and immunodeficiency states. Evidence suggests that these peptides can enhance cellular immunity, stimulate the production of cytokines, and improve immune surveillance. However, while the results are promising, the body of evidence is still evolving, and most studies indicate modest benefits rather than dramatic effects. Regulatory approval for thymic peptides varies by country, reflecting ongoing debate about their clinical utility. In summary, there is scientific rationale and some clinical validation for the use of specific peptides to support thymic function and immune health, but the strength of evidence is moderate rather than robust, and further large-scale, well-controlled studies are needed to confirm their efficacy.